EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase IV)

A Genetic Variant of TLR6 Predicts HBsAg Decline After Pegylated Interferon‐Alpha Treatment in HBeAg‐Positive Chronic Hepatitis B

Wanting Zeng, Jialin Wang, Xinghe Liang, Jia Hou, Jianjun Chen, Xinghua Pan, Bing Zhou, Jinlin Hou, De-Ke Jiang iD

Journal of Medical Virology · 2026-03 · 98 (3)

DOI: 10.1002/jmv.70872 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Medical Virology, online erschienen am 13.03.2026. Verfasst von Wanting Zeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Prevention and Treatment of Multiple Organ Injuries, MOE Key Laboratory of Infectious Diseases Research in South China, Gu…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Interferon-alpha, Antiviral Agents, Hepatitis B e Antigens. Die Arbeit nennt 52 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Guangxi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although toll‐like receptor 6 ( TLR6 ) plays an important role in innate immunity and host antiviral responses, its impact on pegylated interferon‐alpha (PegIFNα) treatment efficacy in chronic hepatitis B (CHB) remains unclear. We aimed to investigate whether genetic variations of TLR6 are associated with the response to PegIFNα treatment. This study included 945 HBeAg‐positive CHB patients treated with PegIFNα for at least 48 weeks and followed for 24 weeks from two multicenter phase IV trials (Cohort 1, n = 238; Cohort 2, n = 707). Across the TLR6 gene, 13 tag‐SNPs were selected. Furthermore, a polygenic score (PGS) was developed by incorporating the newly identified variant of TLR6 and two previously reported SNPs ( CD55 _rs28371597 and CXCR4 _rs28367495). Both TLR6 tag‐SNPs and PGS were tested their associations with treatment efficacy. Among the 13 tag‐SNPs, TLR6 _rs7696175 ( C > T ) was identified as the most significantly associated variant with HBsAg decline at week 72 in both cohorts. The T allele of TLR6 _rs7696175 was significantly associated with greater HBsAg decline, especially higher rates of decline ≥ 1 log 10 IU/mL and ≥ 2 log 10 IU/mL at week 72 (Cohort 1 + 2: p ≤ 0.001 for all associations). Moreover, the PGS integrating TLR6 _rs7696175 and two previously reported SNPs significantly improved prediction accuracy for HBsAg decline at week 72 (Cohort 1 + 2: p < 0.001 for all comparisons) and outperformed single SNPs. Overall, this study identifies TLR6 _rs7696175 as a novel genetic biomarker and demonstrates the superiority of a compact PGS for predicting HBsAg decline in PegIFNα‐treated CHB patients, facilitating personalized treatment for CHB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicInterferon-alphaAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensPolyethylene GlycolsHumansPolymorphism, Single NucleotideFemaleAdultMaleTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

HBsAg declinehepatitis B viruspegylated interferon‐alphapolygenic scoresingle nucleotide polymorphismtoll‐like receptor 6

Substanzen

Interferon-alphaAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensPolyethylene Glycols

Autor:innen und Institutionen

  • National Key Laboratory of Prevention and Treatment of Multiple Organ Injuries, MOE Key Laboratory of Infectious Diseases Research in South China, Guangdong Provincial Key Laboratory for Prevention and Control of Major…
  • Department of Pathology, Key Laboratory of Molecular Pathology in Tumors of Guangxi Higher Education Institutions, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
  • Medical Simulation Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
  • Precision Regenerative Medicine Research Centre, Medical Science Division, and State Key Laboratory of Quality Research in Chinese Medicine, University of Science and Technology, Macau, China.

ORCID-Profile: De-Ke Jiang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangxi
  • GuangDong Basic and Applied Basic Research Foundation
  • Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
  • Innovative Research Team Project of Guangxi Province
  • Nanfang Hospital, Southern Medical University
  • National Basic Research Program of China

Zitieren

APA

Zeng, W., Wang, J., Liang, X., Hou, J., Chen, J., Pan, X., Zhou, B., Hou, J., & Jiang, D. K. (2026). A Genetic Variant of TLR6 Predicts HBsAg Decline After Pegylated Interferon‐Alpha Treatment in HBeAg‐Positive Chronic Hepatitis B. Journal of Medical Virology, 98(3). https://doi.org/10.1002/jmv.70872

Vancouver

Zeng W, Wang J, Liang X, Hou J, Chen J, Pan X, et al. A Genetic Variant of TLR6 Predicts HBsAg Decline After Pegylated Interferon‐Alpha Treatment in HBeAg‐Positive Chronic Hepatitis B. Journal of Medical Virology. 2026;98(3). doi:10.1002/jmv.70872

BibTeX
@article{Zeng2026,
  author = {Zeng, Wanting and Wang, Jialin and Liang, Xinghe and Hou, Jia and Chen, Jianjun and Pan, Xinghua and Zhou, Bing and Hou, Jinlin and Jiang, De-Ke},
  title = {A Genetic Variant of TLR6 Predicts HBsAg Decline After Pegylated Interferon‐Alpha Treatment in HBeAg‐Positive Chronic Hepatitis B},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {3},
  doi = {10.1002/jmv.70872}
}
Kostenlos starten →